286 related articles for article (PubMed ID: 28133796)
1. Germline-targeting immunogens.
Stamatatos L; Pancera M; McGuire AT
Immunol Rev; 2017 Jan; 275(1):203-216. PubMed ID: 28133796
[TBL] [Abstract][Full Text] [Related]
2. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
3. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
[TBL] [Abstract][Full Text] [Related]
4. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.
Yacoob C; Lange MD; Cohen K; Lathia K; Feng J; Glenn J; Carbonetti S; Oliver B; Vigdorovich V; Sather DN; Stamatatos L
PLoS Pathog; 2018 Jun; 14(6):e1007120. PubMed ID: 29933399
[TBL] [Abstract][Full Text] [Related]
5. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
6. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.
Andrabi R; Voss JE; Liang CH; Briney B; McCoy LE; Wu CY; Wong CH; Poignard P; Burton DR
Immunity; 2015 Nov; 43(5):959-73. PubMed ID: 26588781
[TBL] [Abstract][Full Text] [Related]
7. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
Yuan T; Li J; Zhang MY
MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
[TBL] [Abstract][Full Text] [Related]
8. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
Moore PL; Gorman J; Doria-Rose NA; Morris L
Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
[TBL] [Abstract][Full Text] [Related]
9. 'Immunization during ART and ATI for HIV-1 vaccine discovery/development'.
Stamatatos L
Curr Opin HIV AIDS; 2023 Nov; 18(6):309-314. PubMed ID: 37712859
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the membrane-bound form of the chimeric, B/C recombinant HIV-1 Env, LT5.J4b12C.
Das S; Bansal M; Bhattacharya J
J Gen Virol; 2018 Oct; 99(10):1438-1443. PubMed ID: 30129918
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for germline antibody recognition of HIV-1 immunogens.
Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
Elife; 2016 Mar; 5():. PubMed ID: 26997349
[TBL] [Abstract][Full Text] [Related]
12. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.
Dosenovic P; von Boehmer L; Escolano A; Jardine J; Freund NT; Gitlin AD; McGuire AT; Kulp DW; Oliveira T; Scharf L; Pietzsch J; Gray MD; Cupo A; van Gils MJ; Yao KH; Liu C; Gazumyan A; Seaman MS; Björkman PJ; Sanders RW; Moore JP; Stamatatos L; Schief WR; Nussenzweig MC
Cell; 2015 Jun; 161(7):1505-15. PubMed ID: 26091035
[TBL] [Abstract][Full Text] [Related]
13. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
Burton DR; Hangartner L
Annu Rev Immunol; 2016 May; 34():635-59. PubMed ID: 27168247
[TBL] [Abstract][Full Text] [Related]
14. Strategies for a multi-stage neutralizing antibody-based HIV vaccine.
Andrabi R; Bhiman JN; Burton DR
Curr Opin Immunol; 2018 Aug; 53():143-151. PubMed ID: 29775847
[TBL] [Abstract][Full Text] [Related]
15. Identification and specificity of broadly neutralizing antibodies against HIV.
McCoy LE; Burton DR
Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814
[TBL] [Abstract][Full Text] [Related]
16. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
Ahmad M; Ahmed OM; Schnepp B; Johnson PR
Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
18. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
19. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
20. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.
Chen W; Streaker ED; Russ DE; Feng Y; Prabakaran P; Dimitrov DS
Biochem Biophys Res Commun; 2012 Jan; 417(4):1164-9. PubMed ID: 22226962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
